Abstract:
The present invention relates to an antibody directed against HERV-W envelope protein (ENV) for use in the treatment of a group of patients diagnosed with a psychotic disease and characterized with a high level for a cytokine in a body fluid sample.
Abstract:
Methods for viral clearance using low pH hold based on a statistical design of experiment are provided. Several factors are evaluated to characterize the impacts of a low pH hold step for virus inactivation, including the factors of pH conditions, conductivity conditions, protein type, temperature, acid titrant, spike timing, and post-spike filtration. In addition to the effect of pH on virus inactivation, an increase in ionic strength through manipulating the conductivity can be a key component that influences virus inactivation kinetics.
Abstract:
A peptide domain necessary for an interaction between an envelope of a virus belonging to an HERV-W interference group and an hASCT receptor comprises (i) an N-terminus motif having an amino acid sequence selected from the group consisting of: SEQ ID No. 1 to SEQ ID No. 29, (ii) a C-terminus motif having an amino acid sequence selected from the group consisting of: SEQ ID No. 30 to SEQ ID No. 40, and (iii) at least one motif between the N-terminus and the C-terminus, and having an amino acid sequence selected from the group consisting of: SEQ ID No. 41, SEQ ID No. 42 and SEQ ID No. 73.
Abstract translation:属于HERV-W干扰组的病毒的包膜与hASCT受体之间的相互作用所必需的肽结构域包含(i)具有选自下组的氨基酸序列的N末端基序:SEQ ID No. 1至SEQ ID No.29,(ii)具有选自SEQ ID No.30至SEQ ID No.40的氨基酸序列的C末端基序,和(iii)至少一个位于 N-末端和C-末端,并且具有选自SEQ ID No.41,SEQ ID No.42和SEQ ID No.73的氨基酸序列。
Abstract:
The invention relates to an improved assay for detecting antibodies in a tissue sample from individuals who test seronegative by conventional assay techniques, thus aiding in the diagnosis of possible pathogenic infections. Specifically, the invention relates to improved assay methods and kits that enable efficient detection of antibodies against a viral infection.
Abstract:
Disclosed are the simian T-cell lymphotropic virus type 3 subtype D (STLV-3 subtype D), isolated nucleic acid molecules encoding STLV-3 subtype D polypeptides, such as STLV-3 subtype D envelope, protease, polymerase, tax, rex, and capsid polypeptides, isolated polypeptides encoded by such nucleic acids. Methods are also disclosed for detecting STLV-3 subtype D, for example by detecting a STLV-3 subtype D nucleic acid or polypeptide in the sample. Accordingly, probes, primers, and antibodies for use in detecting STLV-3 subtype D nucleic acids or polypeptides are disclosed. Therapeutic compositions which include isolated nucleic acid molecules encoding a STLV-3 subtype D polypeptides or isolated polypeptides encoded by such nucleic acid molecules are also disclosed.
Abstract:
The present invention provides an antibody that recognizes a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 15 in the Sequence Listing and has an anti-arthritic function, or a functional fragment thereof.
Abstract translation:本发明提供一种抗体,其识别包含序列表中SEQ ID NO:15所示的氨基酸序列的多肽,并具有抗关节炎功能或其功能片段。
Abstract:
The present invention provides antigenic polypeptides derived from the melanoma-associated endogenous retrovirus (MERV). These antigens are useful compounds for the detection of cancerous cells and melanoma-diagnosis as well as melanoma-prognosis. Furthermore these antigenic polypeptides of the present invention form the basis for anti-cancer vaccines.
Abstract:
The present invention provides antibodies, or fragments thereof, for isolating and/or identifying epitopes of an endogenous retrovirus, preferably of a melanoma associated endogenous retrovirus, and hybridoma cells producing said antibodies. The antibodies are useful especially for the treatment and diagnosis of cancer. Further, the present application covers diagnostic kits for the detection of cancer cells, especially of melanoma cells and methods for cancer diagnosis using said antibodies.
Abstract:
The invention relates to a peptide domain required for interaction between the envelope of a virus pertaining to the HERV-W interference group and a hASCT receptor, comprising an N end point and a C end point. Said peptide domain is defined, at the N end point thereof, by a pattern formed by the amino acids L (Z)-proline-cysteine-X-cysteine in which Z is any amino acid, is a whole number between 2 and 30, and X is any amino acid, and at the C end point thereof, by a pattern formed by the amino acids serine-aspartic acid-Xa-Xb-Xc-Xd-Xe-aspartic acid-Xf-Xg-(Z) in which Xa, Xb, Xc, Xd, Xe, Xf, Xg are any amino acids, Z is any amino acid, B is a whole number between 15 and 25, preferably 20. The peptide domain comprises, between the N end point and the C end point, at least one pattern selected from the following patterns: a pattern formed by the amino acids cysteine-X2-X3-X4-X5-X6-cysteine in which X2, X3, X4, X5, X6 are any amino acids, and a pattern formed by the amino acids cysteine-X7-X8-X9-X10-X11-X12-X13-X14-X15-cysteine-trytophane in which X7, X8, X9, X10, X11, X12, X13, X14, X15 are any amino acids.
Abstract:
A transgenic organism is provided comprising a polynucleotide construct encoding an intracellular antibody which disrupts the catalysis of the production of the xenoantigen galactose α 1,3 galactose and/or a polynucleotide construct which encodes an intracellular antibody which binds specifically to a retrovirus protein, such as a PERV particle protein. Also described are methods for the production of such organisms. Cells, tissues and organs of the transgenic organism may be used in xenotransplantation.